BAYZED HEALTH (02609) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 575 million, representing a year-on-year increase of 0.66%. The company recorded a net loss attributable to shareholders of RMB 27.62 million, which expanded by 139.18% compared to the same period last year. Basic loss per share was RMB 0.02.